Application of antibiotics in treatment of coronavirus disease 2019 in a designated hospital.
10.11817/j.issn.1672-7347.2020.200291
- Author:
Wenbin LI
1
;
Qiang ZHANG
2
;
Tonghui WANG
3
Author Information
1. Department of Pharmacy, 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050. yfcs2002@163.com.
2. Department of Pharmacy, 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050. 13309485354@163.com.
3. Huoshengshan Hospital, Wuhan 430000. 304981811@qq.com.
- Publication Type:Journal Article
- Keywords:
antibiotics;
coronavirus disease 2019;
pneumonia;
service condition
- MeSH:
Anti-Bacterial Agents;
classification;
therapeutic use;
Betacoronavirus;
Coronavirus Infections;
drug therapy;
Humans;
Pandemics;
Pneumonia, Viral;
drug therapy
- From:
Journal of Central South University(Medical Sciences)
2020;45(5):571-575
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To explore the prescribing habits of doctors, and to provide basis for rational use of antibiotics in clinical practice via investigating and analyzing the applications of antibiotics in treatment of coronavirus disease 2019 (COVID-19) in the designated hospital.
METHODS:Specification, quantity, amount, defined daily dose system (DDDs), defined daily dose consumption (DDDc), antibiotics use density (AUD), composition, frequency of use, combined use of antibacterial drugs used in the hospital were analyzed between Feb. 2020 and Mar. 2020.
RESULTS:A total of 25 antibiotic drugs in 12 categories were used. The total cost for antibiotic drugs was 1 million 238 thousand yuan, in which quinolone accounts for 48%, the third generation cephalosporin/lactamase inhibitors accounts for 15.86%, antifungals accounts for 14.17%, oxazolidone accounts for 13.46%, and carbapenms account for 12.73%. The top three drugs of DDDs and AUD were moxifloxacin hydrochloride tablets, moxifloxacin hydrochloride and sodium chloride injection, cefoperazone sodium and sulbactam sodium for injection. The proportion of patients who had been used more than two kinds of antibiotics was 22.36%.
CONCLUSIONS:Broad-spectrum, high-potency antibiotics are used at the beginning of COVID-19 treatment. The varieties of antibiotics meet the requirements of the management of antibiotics, and the utilization rate of antibiotics and the cost proportion of antibiotics in COVID-19 patients are within a reasonable range.In the future, for the treatment of COVID-19, we should continue to summarize the experience, improve the strategies, and rationally apply antibiotics on the basis of guidelines.
